BAYZF - ESSA Pharma: Update Including Clinical Collaboration Agreement With Janssen
- On January 13, ESSA announced a collaboration agreement with Janssen to evaluate ESSA's EPI-7386 in combo with Janssen's apalutamide and in combo with abiraterone acetate plus prednisone in patients with mCRPC.
- EPI-7386 is a novel approach to treat prostate cancer by targeting the N-terminal domain androgen receptor inhibitor. EPI-7386 is currently in Phase 1 clinical trials which began last July.
- Poster presentation of additional pre-clinical data Feb. 11-13th at ASCO GU and in April at AACR, with initial clinical data expected in June at ASCO and in September at ESMO.
- EPI-7386 is a next-generation Aniten; 20 times more potent, more targeted, longer-lasting (greater than 24-hour half life), easier to manufacture and more stable than ESSA's first-generation Aniten EPI-506.
- Pre-clinical data suggests EPI-7386 may be effective in treating CRPC prostate cancer patients with the AR-V7 full length and splice variant, currently unresponsive to the standard of care anti-androgen drugs.
For further details see:
ESSA Pharma: Update Including Clinical Collaboration Agreement With Janssen